In stock
Padcev 20 mg Powder for concentrate for solution for infusion Vial
In stock
Only 1 left
SKU
10331014313
Padcev 20 mg is a prescription-only medication containing enfortumab vedotin, an antibody-drug conjugate. It is used to treat specific types of locally advanced or metastatic urothelial cancer. Administered as an intravenous infusion, Padcev targets cancer cells in patients who have received prior therapies.
Product Details
Padcev 20 mg Powder for concentrate for solution for infusion is a highly specialized prescription medication used in the treatment of certain types of cancer.
Manufactured by Astellas Pharma, Padcev contains the active ingredient enfortumab vedotin.
This medication is an antibody-drug conjugate (ADC) designed to deliver a potent anticancer agent directly to cancer cells.
Benefits of Use
- Targets specific cancer cells, potentially reducing harm to healthy cells.
- Approved for treating adult patients with locally advanced or metastatic urothelial cancer.
- Offers a treatment option for patients who have progressed on prior therapies, including PD-1/L1 inhibitors and platinum-containing chemotherapy.
How to Use
Padcev is administered by a healthcare professional in a clinical setting.
- The powder in the vial is reconstituted with sterile water for injection.
- The reconstituted solution is then further diluted in an infusion bag.
- The final solution is administered as an intravenous (IV) infusion over 30 minutes.
- The dosage and schedule are determined by your doctor based on your specific condition and body weight.
- It is typically given on Days 1, 8, and 15 of a 28-day cycle.
Caution & Warnings
- Padcev can cause severe skin reactions. Patients should monitor for rash and report any changes promptly.
- Hyperglycemia (high blood sugar) can occur. Blood glucose levels should be monitored before and during treatment.
- Peripheral neuropathy (nerve damage) is a common side effect; symptoms should be reported immediately.
- Pneumonitis (inflammation of the lungs) may occur; patients should report new or worsening respiratory symptoms.
- Embryo-fetal toxicity: Padcev can cause harm to a fetus. Pregnant women should not use it, and effective contraception is required for patients of reproductive potential.
- Lactation: Breastfeeding is not recommended during treatment and for a specified period after the last dose.
- Liver toxicity may occur. Liver function tests should be monitored.
Ingredients
Active ingredient: Enfortumab Vedotin.
Each vial contains 20 mg of enfortumab vedotin.
Inactive ingredients: Histidine, Histidine hydrochloride monohydrate, Trehalose dihydrate, Polysorbate 80.
| Gtin | 1811246255 |
|---|---|
| Recommended Sale Price | 2880.5 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | ENFORTUMAB |
| SFDA Reg. No | 1811246255 |
| IBC | 1811246255 |
| Drug Type | Prescription |
| Scientific Name | Enfortumab Vedotin |
| Strength | 20 |
| Strength Unit | mg |
| Form | Powder for solution for infusion |
| Admin Route | Intravenous |
| Size | 1 |
| Size Unit | Vial |
| Package Types | Vial |
| Package Size | 1 Vial |
| Storage conditions | Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. |
| Refrigerator Storage | Yes |
Products you might like
